Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Paddock Laboratories, Inc. Recalls Select Lots of Ciclopirox Gel 0.77%
Paddock Laboratories, Inc. has recalled select lots of Ciclopirox Gel, 0.77%. The following lot numbers have been recalled because samples from these lots did not pass the manufacturer's routine tests for impurities and by-products from chemical breakdown over time: 2010433330 and 2011155328 Ciclopirox Gel is used in the treatment of skin inflammation. Ciclopirox Shampoo is also sold under the brand name Loprox. No other lots, strengths, or brands of Ciclopirox were involved in this recall. To view the FDA notice about this recall, please visit: http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm286943.htm
Learn More

Warner Chilcott Company Recalls Several Lots of Ovcon 50 Tablets
Warner Chilcott Company has recalled several lots of Ovcon 50 (norethindrone and ethinyl estradiol ) Tablets, 1 mg/50 mcg. The following lot numbers have been recalled because routine testing found that the amount of active ingredient was too low in several samples from these lots: 02260F, 504705A, and 504705B Ovcon 50 contains the active ingredient norethindrone and ethinyl estradiol and is commonly used in the prevention of contraception. This recall alert only applies to the select lots of Ovcon 50 (Norethindrone and ethinyl estradiol ) Tablets, 1 mg/50 mcg. No other norethindrone and ethinyl estradiol products were involved in this recall. To view the FDA notice about this recall, please visit: http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm286943.htm
Learn More

Date Published Title Drug Source
2012-02-02 Paddock Laboratories, Inc. Recalls Select Lots of Ciclopirox Gel 0.77% Ciclopirox FDA
2012-02-02 Warner Chilcott Company Recalls Several Lots of Ovcon 50 Tablets Norethindrone with Ethinyl Estradiol FDA
2012-02-02 Taro Pharmaceuticals USA, Inc. Recalls Several Lots of Fluocinonide, Ointment USP, 0.05% Fluocinonide FDA
2012-02-02 Sandoz Inc. Recalls Single Lot of Fluoxetine Capsules 10 mg Fluoxetine FDA
2012-02-01 Pfizer Announces Voluntary Nationwide Recall Of Lo/Ovral-28 And Norgestrel/Ethinyl Estradiol Tablets Due To Tablet Mix-Up Ethinyl Estradiol with Norgestrel Manufacturer
2012-01-30 Treanda (bendamustine HCL) Recall - Particles Found in Vial Bendamustine FDA
2012-01-26 FDA Makes Changes to Risk Evaluation and Mitigation Strategies (REMS) Program for Nplate (Romiplostim) and Promacta (Eltrombopag) Romiplostim FDA
2012-01-24 FDA Announces New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab) Natalizumab FDA
2012-01-18 Rexall, Inc Issues Allergy Alert and Recall of Single Lot of Calcium 1200mg plus Vitamin D 1000 IU Softgels FDA
2012-01-18 New Study Raises Concerns about Daily Aspirin Use in People Without a History of Heart Disease Aspirin MediGuard CRT
2012-01-16 New Boxed Warning for Progressive Multifocal Leukoencephalopathy (PML) and Contraindication for Adcetris (Brentuximab vedotin) Brentuximab Vedotin FDA
2012-01-13 New Study Study Finds Small Increased Risk of Heart Attack in Patients Treated with Pradaxa Dabigatran MediGuard CRT
2012-01-09 Possible Supply Shortage and Rare Tablet Mix-up For Opioid Pain Medications from Endo Pharmaceuticals Acetaminophen with Oxycodone FDA
2012-01-09 Novartis Provides Important Information about Tekturna and Aliskiren-Based Products Aliskiren Manufacturer
2012-01-09 Novartis Consumer Health Inc. Issues Voluntary Recall Of Certain Excedrin, Bufferin, and Gas-X Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps FDA
2012-01-04 Teva Pharmaceuticals USA Recalls Single Lot of Hydralazine Hydrochloride Tablets, USP, 25 mg Hydralazine FDA
2012-01-04 Alkem Laboratories Recalls Several Lots of Metformin Hydrochloride, Tablets USP, 850 mg and 1000 mg Metformin FDA
2012-01-04 Mylan Pharmaceuticals Inc. Recalls Single Lot of Verapamil HCI Extended-Release Capsules, 180 mg Verapamil FDA
2012-01-04 Biovail Corp. Recalls Single Lot of Wellbutrin XL 150 mg Bupropion FDA
2012-01-02 FDA Approves Risk Management Plan for Entire Class of Transmucosal Immediate-Release Fentanyl (TIRF) Medicines Fentanyl FDA
Back to Consumer Med Safety